Larimar Therapeutics, Inc. (LRMR) has a negative trailing P/E of -2.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 18.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -38.40%, forward earnings yield 5.34%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.5 | 0.06 | 0.71 | 0.00 | - |
| 2017 | -2.4 | 0.23 | 1.62 | 0.00 | - |
| 2018 | -2.6 | -6.57 | 1.71 | 0.00 | - |
| 2019 | -5.3 | 0.06 | -176.84 | 0.00 | - |
| 2020 | -6.0 | -0.14 | 2.84 | 0.00 | - |
| 2021 | -3.7 | 0.21 | 2.88 | 0.00 | - |
| 2022 | -3.0 | 0.06 | 0.96 | 0.00 | - |
| 2023 | -5.4 | 0.15 | 2.44 | 0.00 | - |
| 2024 | -2.9 | -0.05 | 1.38 | 0.00 | - |
| 2025 | -1.7 | -0.02 | 3.56 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-25.44 | $0.00 | $-57.88M | - |
| 2017 | $-22.76 | $0.00 | $-52.03M | - |
| 2018 | $-22.85 | $0.00 | $-61.37M | - |
| 2019 | $-2.51 | $0.00 | $-23.13M | - |
| 2020 | $-3.56 | $0.00 | $-42.33M | - |
| 2021 | $-2.93 | $0.00 | $-50.31M | - |
| 2022 | $-1.33 | $0.00 | $-34.18M | - |
| 2023 | $-0.84 | $0.00 | $-36.95M | - |
| 2024 | $-1.32 | $0.00 | $-80.6M | - |
| 2025 | $-2.27 | $0.00 | $-165.67M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.96 | $-2.99 – $-1.40 | $2.32M | $443.14K – $5.84M | 7 |
| 2027 | $-1.54 | $-2.44 – $-1.13 | $62.61M | $10.39M – $116.49M | 5 |
| 2028 | $-0.72 | $-2.00 – $1.02 | $161.38M | $161.38M – $161.38M | 6 |
| 2029 | $0.26 | $-0.01 – $0.77 | $313.48M | $59.96M – $789.97M | 4 |
| 2030 | $1.90 | $-0.10 – $5.64 | $555.68M | $106.29M – $1.4B | 2 |
